Management of macular oedema in diabetic patients undergoing cataract surgery. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Boscia, Francesco; Giancipoli, Ermete; D'Amico Ricci, Giuseppe; Pinna, Antonio
• Is Part Of: Current opinion in ophthalmology. Volume 28:Issue 1(2017:Jan.)
• Publication Date: 2017-01
• Subjects: cataract surgery -- diabetic macular oedema -- intravitreal therapy -- postsurgical macular oedema -- topical NSAIDs; Ophthalmology -- Periodicals; Eye Diseases -- Indexes; Eye Diseases -- Periodicals; Review Literature -- Indexes; Review Literature -- Periodicals; Vision Disorders -- Indexes; Vision Disorders -- Periodicals; 617.7
• DOI: 10.1097/ICU.0000000000000328
• Languages: English
• ISSNs: 1040-8738

Abstract

Abstract : Purpose of review: The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery. Recent findings: Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects. By contrast, in patients with a diagnosis of diabetic macular oedema (DME) at the time of cataract surgery, intravitreal therapy, both with anti-VEGF drugs and steroids, appears to be the best approach in order to control PME and achieve a good visual outcome. Conclusion: All diabetic patients undergoing cataract surgery should be treated with topical NSAIDs to prevent PME. Intravitreal anti-VEGF drugs and steroids, combined with cataract surgery, should be reserved for patients with preexisting DME.